Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Air Products & Chemicals, Inc. (APD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Air Products & Chemicals, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Air Products & Chemicals, Inc. trades at $308.56 (market cap $68.88B). The key difference: Air Products & Chemicals, Inc. is far larger — about 2.3× Alnylam Pharmaceuticals, Inc.'s market cap, and Air Products & Chemicals, Inc. pays a 2.34% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | APD | |
|---|---|---|
Market Cap | $29.60B | $68.88B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $314.19 |
52-Week Low | $205.48 | $230.42 |
Enterprise Value | $27.56B | $86.06B |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Air Products and Chemicals (APD) trades at $304.01, down 1.35% with strong technical momentum and bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, though recent profitability metrics show negative net income margin and ROE. Recent news highlights a major semiconductor supply deal in Taiwan and raised guidance, while analyst consensus remains strongly positive with a $346 price target representing 14% upside potential.
The outlook remains constructive given earnings momentum and strategic contract wins, but investors face risks from elevated valuation multiples and recent negative profitability. The stock's technical strength and institutional support provide near-term catalysts, though margin recovery and debt management will be critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →
